Horizon Pharma apparently hasn't been deterred by the ongoing drug pricing debate—or repeated criticism of its own price hikes. The specialty drugmaker recently jacked up the list price of its combo painkiller Vimovo to almost $3,000, despite the fact that its separate ingredients are available as individual generics for as little as $40.Original Article
Horizon’s faced repeated price-hike criticism, but Vimovo just got its 11th raise—to almost $3,000
